 Lille, France; Cambridge, MA; January 6, 2021 - GENFIT Nasdaq and Euronext: GNFT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that it will be presenting at the following upcoming investor conferences and host a Primary Biliary Cholangitis PBC KOL event for the financial community. 